Clinical trials: Virus Disease
HIV Infections
TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options
This is an open-label safety study to provide early access to TMC114 for HIV-1 infected patients who have failed and exhausted regimens based on commercially available antiretroviral (ARV) therapy and who are ineligible for…
- Trial name
- NCT00115050
- Testing
- TMC114
- Volunteers
- 260 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infections
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDS
To determine the safety and efficacy of zidovudine (AZT) treatment combined with syngeneic or HLA identical allogeneic lymphocyte transfer in the presence of interleukin 2 (IL-2) as a treatment for AIDS.
- Trial name
- NCT00002285
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
Chikungunya Fever, Chikungunya Virus
Trial of an Inactivated Chikungunya Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation Phase 1 trial, evaluating dosages of 2.5 mcg and 8 mcg of HydroVax-005 CHIKV vaccine given intramuscularly on Day 1 and Day…
- Conditions
- Chikungunya Fever, Chikungunya Virus, Chikungunya
- Trial name
- NCT06669208
- Testing
- HydroVax-005 CHIKV
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Najit Technologies, Inc.
Papillomavirus Infections
Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED)
This is an immunogenicity and safety study of Gardasil (V501) in females 9 to 23 years of age in Korea.
- Trial name
- NCT00157950
- Testing
- Gardasil™
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants
The purpose of this study is to evaluate the single-dose pharmacokinetics and pivotal bioequivalence of Darunavir (DRV) 800 milligram (mg), Emtricitabine (FTC) 200 mg, and tenofovir alafenamide (TAF) 10 mg when administered as a…
- Trial name
- NCT02578550
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC), Emtricitabine/tenofovir alafenamide FDC, Darunavir
- Where
- Netherlands
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
Lymphatic Disease, HIV Infections
A Study of Isoprinosine in Patients With Lymph Node Disease
The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include: Signs and symptoms: Lymphadenopathy. Fever.
- Trial name
- NCT00002297
- Testing
- Inosine pranobex
- Where
- United States
- Sponsor
- Newport Pharmaceuticals International
Hepatitis C, Chronic
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.
This 4 arm study will compare the safety and tolerability of HCV polymerase inhibitor pro-drug in combination with PEGASYS +/- COPEGUS with the standard of care therapy of PEGASYS + COPEGUS, in treatment-naive patients with CHC…
- Trial name
- NCT00377182
- Testing
- Copegus, PEGASYS, RO5024048 1500mg
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 107 people
- Sponsor
- Hoffmann-La Roche
Corona Virus Infection, Covid19
Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19
A preparation of CimertrA, comprising Artemisinin, Curcumin, and Boswellia, and Vitamin C in a nanoparticular formulation, is proposed as a treatment for the disease associated with the novel coronavirus SARS-CoV-2.
- Conditions
- Corona Virus Infection, Covid19, SARS-CoV Infection
- Trial name
- CimetrA (NCT04802382)
- Testing
- Confirm SARS-CoV-2 infection, Physical Examination, Vital Signs
- Where
- 2 sites in Israel
- Volunteers
- 252 people
- Sponsor
- MGC Pharmaceuticals d.o.o
Infections, Rotavirus, Rotavirus Vaccines
Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants
This study is undertaken to provide the regulatory authorities in Japan with immunogenicity, efficacy, safety and reactogenicity data of GSK Biologicals' Human Rotavirus [HRV] vaccine, given as a 2-dose primary vaccination, in…
- Trial name
- NCT00480324
- Testing
- Rotarix
- Where
- 20 sites in Japan
- Volunteers
- 765 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
The Safety and Effectiveness of Retrovir Plus HIVID Combined With Either Nevirapine or Invirase in the Treatment of HIV Infection
To evaluate the tolerance and immunologic and virologic effects of multidrug combinations of antiretrovirals in patients with HIV infection.
- Trial name
- NCT00002347
- Testing
- Saquinavir, Nevirapine, Zidovudine
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- Parexel
Influenza
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00971425
- Testing
- Pandemrix (GSK investigational influenza GSK2340272A vaccine), Fluarix™
- Where
- 6 sites in Germany
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine
The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
- Trial name
- NCT05669625
- Testing
- Investigational live attenuated varicella vaccine
- Where
- 13 sites in China
- Volunteers
- 12,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
HIV Infections
Pharmacokinetics and Efficacy of Multiple Dosing of Lipovirtide for Injection in HIV-infected Patients
Primary Objectives 1.Evaluation of safety and tolerability after repeated administration of injectable Lipivirtide in HIV-infected patients not receiving antiretroviral therapy Secondary Objectives 1.
- Trial name
- NCT05349968
- Testing
- Lipovirtide for injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
HCV Infection
Clinical Study to Evaluate the Performance of the INSTI® HCV Antibody Test for CLIA-Waived Use
multicenter prospective study to evaluate the clinical performance, usability and contrived result interpretation of the INSTI® HCV Antibody Test (INSTI HCV) with fingerstick (FS) whole blood specimens from participants with…
- Trial name
- NCT07904416
- Testing
- INSTI HCV Antibody Test
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Sars-CoV-2 Infection
AIDI - Research & Development of a Multisensor-Based Machine Learning Technology for Real-Time Automated Detection of COVID-19 Decompensation
The AIDI study has to phases. It's purpose is to capture vital signs using a non-invasive, hand-held, home monitoring device (MouthLab Device) from individuals with COVID-19 or who test positive for SARS-CoV-2 (Phase I) and use…
- Trial name
- AIDI (NCT05220306)
- Testing
- Monitoring of vital signs
- Where
- United States
- Sponsor
- AIDAR Health, Inc.
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) and SOF/VEL FDC and ribavirin (RBV) for 12 weeks in participants with…
- Trial name
- NCT02781558
- Testing
- SOF/VEL, RBV
- Where
- 28 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Gilead Sciences
HIV Infections
Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients
Objectives of the study were to evaluate the efficacy and safety of two different doses of tipranavir (TPV) in combination with ritonavir (TPV/r) compared with a standard dual PI combination of saquinavir (SQV) and ritonavir…
- Trial name
- NCT02239835
- Testing
- Tipranavir (TPV) low dose, Tipranavir (TPV) high dose, Ritonavir low dose
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Mycobacterium Avium-Intracellulare Infection, HIV Infections
An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy
To evaluate the efficacy and safety of azithromycin given chronically for the treatment of Mycobacterium avium (MAC) bacteremia in patients failing or intolerant of current available MAC therapy.
- Trial name
- NCT00002089
- Testing
- Azithromycin
- Where
- United States
- Sponsor
- Pfizer
Motavizumab Administration for a Second Season for RSV Prophylaxis
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children
The primary objective of this study was to determine the effect on immune reactivity to motavizumab (MEDI-524) of monthly intramuscular (IM) doses of motavizumab (MEDI-524) administered for a second season in children.
- Trial name
- NCT00113490
- Testing
- motavizumab (MEDI-524), palivizumab 15 mg/kg
- Where
- 6 sites in Brazil, Chile
- Volunteers
- 136 people
- Sponsor
- MedImmune LLC
Influenza
Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
1. To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level delivered i.m., or the 2.0 µg dose level delivered s.c.
- Trial name
- NCT00921947
- Testing
- VAX102
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.